Bullous Pemphigoid After Four Months of High-Dose Steroids

Before You Read This

This is a record of one person, drawn from a case report in our own files. It is not evidence of a rate. Four case reports stacked together would not be evidence of a rate either.

Everything clinical below — her age, her drug doses, her blister count, the figures in the table — is taken from that record. Where the record is silent, this page is silent. We have not filled gaps with what would have been plausible, because a plausible number attributed to a real patient is a lie, and it is the specific lie this field tells most often.

Where we think the original record is itself unreliable, we say so. There are two places where we do.

The Presentation

A woman of sixty-eight, a retired schoolteacher, with bullous pemphigoid confirmed the correct way — by biopsy and immunofluorescence, not by anyone's impression of a rash. The disease had begun eight months before she came to us.

The skin at presentation: twenty to thirty blisters, some fresh, some crusted, across her limbs and trunk. Tense and fluid-filled, which is what pemphigoid produces, because the split is beneath the epidermis at the hemidesmosomes — so the blister has a thick roof and it lasts, unlike the flaccid, immediately-rupturing blister of pemphigus. Intense itching. Heat in the lesions. The record notes emotional distress, which in a disease that itches, disfigures, and does not resolve is not a soft finding.

She was not untreated. She had been on high-dose corticosteroids for four months, peaking at sixty milligrams of prednisolone a day, with antihistamines and topical steroids alongside. She also had type 2 diabetes, described in the record as mild, along with hypertension and chronic acidity.

The Actual Problem

Here is what makes this case worth publishing, and it is not the blisters.

The steroid had worked. The initial symptoms had subsided. But every attempt to taper produced a flare worse than the one before — and in the meantime the drug had begun charging its own price: disturbed sleep, blood sugar climbing, facial puffiness. Her sugars were unstable, and the record attributes that directly to the steroid, which is the usual and correct explanation.

So she was in the trap that brings most people to a page like this one. The drug controls the disease. The drug cannot be reduced, because the disease returns worse each time it is tried. And the drug is doing damage on a timescale of months.

That cycle — not the emergency — is the situation this protocol is designed for.

What Was Done, and What Has Changed Since

The record describes a phased course run over roughly six months, with the formulations revised as she moved through it. Three things about it should be stated plainly rather than smoothed over.

This record predates the current sequence. The course as it was run for her began with clearance and inflammation control together, in the first three weeks. EPOH as it now stands would not do that. It runs Lowering Inflammatory Load and Internal Healing and Gut Repair first, and introduces Functional Detox only once those are stable — because clearance work started too early mobilises load faster than the body can clear it, and that makes blistering disease worse. This is not a retrospective criticism of her care; she did well. It is the honest statement that if she presented today, her first three weeks would look different.

It was not remote. The record uses the language of an in-person episode of care. The protocol today has no clinic visit at any stage: formulations couriered to the patient and taken at home, with no procedure and no in-clinic therapy of any kind. Her case describes something we no longer do.

We are not reproducing the original title. The case was published under a heading claiming the disease had been healed without steroids. We are not repeating that claim, for reasons set out below.

What the Record Reports

At three weeks: new blister formation stopped, itching had fallen substantially, digestion had improved.

That is earlier than we would now lead anyone to expect. The current protocol tells patients to expect no visible surface change for the first four to eight weeks, and we would rather set that expectation and be beaten by it than set the reverse and have people quit in week five.

Over the following months: existing blisters healed without scarring, and post-blister pigmentation lightened.

At six months, the record's own table reads:

• Blister count: twenty to thirty at the start; none at six months.
• Itching: severe, scored eight out of ten at the start; mild, scored one to two, at six months.
• Relapses: every two to three weeks at the start; none recorded from the fourth month onward.
• Fasting blood sugar: one hundred and fifty to one hundred and sixty milligrams per decilitre at the start; ninety-eight to one hundred and four at six months.
• Steroid: high dose at the start; recorded as stopped after five weeks.

The Two Things We Will Not Do With That Table

We will not tell you that we stopped her steroid

The record states that the steroid was stopped after five weeks. It does not state who made that decision, on what evidence, or with whose agreement. We are not going to infer it, because the inference people would draw is the dangerous one.

So, unambiguously: we do not taper steroids. We have never tapered anyone's steroids. Every decision about prednisolone — and about rituximab, azathioprine, mycophenolate, or dapsone — belongs to the doctor who prescribed it. Sudden steroid withdrawal risks adrenal insufficiency, and a rebound flare in a blistering disease can be dangerous.

If you take one thing from this page, take that, and not the table.

What a case like this can honestly suggest is narrower: that work on the background against which a taper is attempted may change what a dermatologist sees when they attempt it. It does not suggest that a home protocol removes the need for the drug. We are not saying that, and we would ask you to be suspicious of anyone who does.

We will not tell you that her diabetes was treated

Her fasting sugars fell over the six months. Her steroid dose also fell over the same six months — and high-dose steroid is a well-recognised cause of exactly the hyperglycaemia she had.

Those two facts sit next to each other in the record, and the record does not disentangle them. Neither will we. We do not manage diabetes medication and we make no claims about blood glucose.

What It Reasonably Suggests

Set against all of that, what remains is still worth something.

A woman with biopsy-confirmed pemphigoid, stuck for four months in a taper-and-flare cycle on high-dose steroid, was recorded as having no new blister formation from three weeks, and no active blistering at six months, with itch down from severe to mild.

We cannot tell you that we caused it. She was on conventional treatment, correctly, through the part of the course where the disease turned. Pemphigoid fluctuates on its own. And there is no control arm for a single patient.

That is not false modesty — it is the reason we publish no success rate at all. A case report can tell you that something happened to somebody. It cannot tell you how often, or why, and anyone using one to imply a proportion is performing a trick.

What it can do is show you what the trap looks like from the inside, and that people do sometimes get out of it.

What We Do Not Claim

We do not promise a cure. There is no cure for pemphigoid, from us or from anyone. What we work toward is sustained remission — a quieter disease, fewer new lesions, less itch, less load — and pemphigoid can relapse, which we will not pretend otherwise about.

This is supportive care alongside a dermatologist, never instead of one.

If your disease is widespread, if you have mucosal involvement, if you cannot eat, or if you have any eye symptom at all — grittiness, redness, a foreign-body sensation — that is conventional treatment today, and in the case of the eye, ophthalmology today. Mucous membrane pemphigoid scars the conjunctiva, and that threatens sight.

Nothing on this page is an argument for waiting.